MESOMesoblast Limited
$12.27-32% 1Y
$12.27
$11.9552 weeks$20.96
Is the business good?
How good a business is MESO?
Mesoblast Limited keeps −1061% of every revenue dollar as profit after everything, against −86% for the median Biotechnology name.
−1061%
Net margin · Biotechnology median −86% · 12 months to Q4 2023
Details›
- Net margin12 months to Q4 2023
- −1061%
- R&D as % of revenue
- 685%
- Revenue, trailing twelve months
- $7.7M
- Net income, trailing twelve months
- −$82M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.